HAS authorizes Pfizer’s oral treatment against COVID-19 – 01/21/2022 at 17:15


HAS AUTHORIZES PFIZER’S ORAL TREATMENT AGAINST COVID-19

PARIS (Reuters) – The High Authority for Health (HAS) on Friday authorized early access in France to the Paxlovid® treatment from the Pfizer laboratory for adults suffering from a mild to moderate form of COVID-19 and likely to develop a form serious illness.

“This antiviral is indicated for adults infected with SARS-CoV-2 who do not require oxygen supplementation and who are at high risk of their infection progressing to a severe form of the disease,” the authority said. French regulator in a notice published on its website.

This green light from the HAS follows the positive opinion issued by the National Medicines Safety Agency (ANSM) on this curative treatment.

The Paxlovid treatment combines a new active ingredient (PF-07321332) and ritonavir, an antiretroviral used for a long time in the management of HIV-AIDS, which blocks viral enzymes and therefore makes it possible to increase the effectiveness of the drug.

The treatment, which should be started as soon as possible, comes in the form of two tablets (one for each active ingredient) to be taken orally twice a day for five days.

(Written by Jean-Stéphane Brosse)



Source link -86